{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:24:52Z","timestamp":1770287092431,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cpcardiol.2025.103129","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T06:58:10Z","timestamp":1752821890000},"page":"103129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy"],"prefix":"10.1016","volume":"50","author":[{"given":"Bilal","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-3971","authenticated-orcid":false,"given":"Sanchit","family":"Duhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bansari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Najam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Sajjad","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mubashar","family":"Karamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junaid","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijeta","family":"Keisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Chadi","family":"Alraies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasar","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2025.103129_bib0001","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0003","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis Outcomes Survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103129_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001755","article-title":"Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden","volume":"8","author":"Lauppe","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0006","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103129_bib0007","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe","year":"2022","journal-title":"J Clin Med"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2025.103129_bib0009","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.amjcard.2022.10.014","article-title":"Overview of current and emerging therapies for Amyloid transthyretin cardiomyopathy","volume":"185","author":"Maurer","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamacardio.2020.1738","article-title":"Initial experience prescribing commercial Tafamidis, the most expensive cardiac medication in history","volume":"5","author":"Masri","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.cpcardiol.2025.103129_bib0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506129.2022.2131385","article-title":"Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy","volume":"30","author":"Rettl","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0014","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/ehjci\/jeac049","article-title":"Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis","volume":"23","author":"Giblin","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0016","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","article-title":"Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future","volume":"18","author":"Obici","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0017","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/156800705774322076","article-title":"Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses","volume":"4","author":"Almeida","year":"2005","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0018","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1042\/BJ20040011","article-title":"Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative","volume":"381","author":"Almeida","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0019","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(","volume":"26","author":"Gamez","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic Transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2025.103129_bib0021","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"ATTRibute-CM Investigators. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0022","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1021\/acs.jmedchem.9b01037","article-title":"Binding of monovalent and bivalent ligands by transthyretin causes different short- and long-distance conformational changes","volume":"62","author":"Corazza","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0023","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41598-017-00338-x","article-title":"Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel","volume":"7","author":"Verona","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0024","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0025","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0026","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0027","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0028","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0029","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: First Global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0032","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/AAC.00594-16","article-title":"rRNA binding sites and the molecular mechanism of action of the tetracyclines","volume":"60","author":"Chukwudi","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.635760","article-title":"Doxycycline interferes with Tau aggregation and reduces its neuronal toxicity","volume":"13","author":"Medina","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0034","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2025.103129_bib0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0036","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0037","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0038","doi-asserted-by":"crossref","unstructured":"Ledford H. Landmark CRISPR trial shows promise against deadly disease. Nature. 2021 Jun 29. doi:10.1038\/d41586-021-01776-4. Epub ahead of print.","DOI":"10.1038\/d41586-021-01776-4"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ejhf.2028","article-title":"Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis","volume":"23","author":"B\u00e9zard","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.cpcardiol.2025.103129_bib0041","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00392-022-02035-w","article-title":"Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging","volume":"112","author":"Chamling","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0042","first-page":"146","article-title":"Real-world efficacy of Tafamidis in patients with transthyretin amyloidosis and heart failure","author":"Ghoneem","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2025.103129_bib0043","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1253\/circj.CJ-21-0965","article-title":"Early experience of Tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort","volume":"86","author":"Ochi","year":"2022","journal-title":"Circ J"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280625001495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:08:06Z","timestamp":1753690086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280625001495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0146280625001495"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103129","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103129"}}